Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

27.55USD
23 May 2017
Change (% chg)

$-0.46 (-1.64%)
Prev Close
$28.01
Open
$28.09
Day's High
$28.30
Day's Low
$27.28
Volume
1,220,181
Avg. Vol
1,821,684
52-wk High
$42.49
52-wk Low
$20.68

ACAD.O

Chart for ACAD.O

About

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease... (more)

Overall

Beta: 4.02
Market Cap(Mil.): $3,418.52
Shares Outstanding(Mil.): 122.05
Dividend: --
Yield (%): --

Financials

  ACAD.O Industry Sector
P/E (TTM): -- 139.31 17.29
EPS (TTM): -2.61 -- --
ROI: -68.53 2.29 -5.84
ROE: -68.56 0.06 -5.23

BRIEF-Acadia Pharmaceuticals Q4 loss per share $0.65

* Acadia Pharmaceuticals reports financial results for the fourth quarter and year ended december 31, 2016

Feb 28 2017

Bets on financials, pharma power U.S. hedge funds' strong start to year

NEW YORK Several big-name U.S. hedge fund investors in the fourth quarter moved significant parts of their portfolios into financial and pharmaceutical stocks that are expected to benefit under the Trump administration, helping to power the sector to its best January performance in four years.

Feb 14 2017

Bets on financials, pharma power U.S. hedge funds' strong start to year

NEW YORK, Feb 14 Several big-name U.S. hedge fund investors in the fourth quarter moved significant parts of their portfolios into financial and pharmaceutical stocks that are expected to benefit under the Trump administration, helping to power the sector to its best January performance in four years.

Feb 14 2017

Acadia says Alzheimer's psychosis drug clears mid-stage study

Acadia Pharmaceuticals Inc said on Tuesday its drug to treat psychosis in patients suffering from Alzheimer's disease met its main goal in a mid-stage study, sending its shares up as much as 18.5 percent.

Dec 20 2016

More From Around the Web

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $32.14 +0.02
Eli Lilly and Co (LLY.N) $77.99 +1.01
Eisai Co., Ltd (4523.T) ¥5,990 +32.00

Earnings vs. Estimates